Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Eli Lilly and Company is conducting a Phase 2 clinical study titled A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight. The study aims to evaluate the efficacy and safety of the drug LY3841136 in managing weight among adults with obesity or overweight, highlighting its potential significance in addressing a growing health concern.
The intervention being tested is LY3841136, a drug administered subcutaneously, with the purpose of aiding weight management. The study includes multiple experimental groups receiving different doses of LY3841136, as well as a placebo group for comparison.
This interventional study employs a randomized, parallel-group design with double masking, meaning both participants and investigators are unaware of the group allocations. The primary purpose of the study is treatment-focused, aiming to assess the drug’s effectiveness in weight management.
The study began on February 5, 2024, with an estimated completion timeline of 64 weeks, involving up to 17 visits for participants. The last update was submitted on July 11, 2025, indicating ongoing progress and data collection.
The outcome of this study could significantly impact Eli Lilly’s market position, potentially boosting its stock performance if results are favorable. The weight management market is competitive, with several companies vying for effective solutions, making this study’s results crucial for investor sentiment.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.